share_log

BioCryst Pharma Analyst Ratings

BioCryst Pharma Analyst Ratings

BioCryst 製藥分析師評級
Benzinga ·  2023/09/18 19:16
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/18/2023 45.99% RBC Capital $9 → $10 Upgrades Sector Perform → Outperform
08/04/2023 31.39% RBC Capital $8 → $9 Maintains Sector Perform
08/04/2023 60.58% Jefferies → $11 Upgrades Hold → Buy
08/04/2023 337.96% HC Wainwright & Co. → $30 Reiterates Buy → Buy
08/03/2023 75.18% Needham $14 → $12 Reiterates → Buy
07/13/2023 45.99% B of A Securities → $10 Upgrades Neutral → Buy
05/04/2023 31.39% RBC Capital → $9 Reiterates → Sector Perform
05/04/2023 104.38% Needham → $14 Reiterates → Buy
04/20/2023 45.99% Evercore ISI Group $13 → $10 Maintains Outperform
04/20/2023 104.38% Needham → $14 Reiterates → Buy
03/14/2023 45.99% RBC Capital → $10 Reiterates → Sector Perform
02/22/2023 133.58% JMP Securities → $16 Reiterates → Market Outperform
02/22/2023 104.38% Needham → $14 Upgrades Hold → Buy
02/22/2023 337.96% HC Wainwright & Co. → $30 Reiterates → Buy
11/02/2022 133.58% Evercore ISI Group → $16 Upgrades In-Line → Outperform
11/02/2022 89.78% RBC Capital $14 → $13 Maintains Sector Perform
08/08/2022 Oppenheimer Downgrades Outperform → Perform
08/05/2022 104.38% Barclays $12 → $14 Maintains Equal-Weight
08/05/2022 Oppenheimer Downgrades Outperform → Perform
08/05/2022 104.38% Evercore ISI Group → $14 Downgrades Outperform → In-Line
04/18/2022 89.78% Barclays $22 → $13 Downgrades Overweight → Equal-Weight
04/12/2022 104.38% RBC Capital $16 → $14 Maintains Sector Perform
04/11/2022 104.38% B of A Securities → $14 Downgrades Buy → Neutral
04/11/2022 133.58% Oppenheimer $20 → $16 Maintains Outperform
12/10/2021 133.58% Oppenheimer → $16 Initiates Coverage On → Outperform
11/04/2021 104.38% RBC Capital $16 → $14 Maintains Sector Perform
11/04/2021 148.18% Barclays $21 → $17 Maintains Overweight
08/06/2021 235.77% JMP Securities $22 → $23 Maintains Market Outperform
08/06/2021 Jefferies Downgrades Buy → Hold
08/06/2021 133.58% RBC Capital $13 → $16 Maintains Sector Perform
08/06/2021 206.57% Barclays $20 → $21 Maintains Overweight
08/06/2021 337.96% HC Wainwright & Co. $18 → $30 Maintains Buy
08/03/2021 206.57% Cantor Fitzgerald → $21 Initiates Coverage On → Overweight
03/24/2021 177.37% HC Wainwright & Co. $14 → $19 Maintains Buy
01/22/2021 31.39% RBC Capital $7 → $9 Maintains Sector Perform
12/07/2020 104.38% HC Wainwright & Co. $13 → $14 Maintains Buy
11/24/2020 75.18% Evercore ISI Group → $12 Initiates Coverage On → Outperform
06/17/2020 BTIG Initiates Coverage On → Neutral
05/05/2020 2.19% Barclays $4 → $7 Upgrades Equal-Weight → Overweight
11/15/2019 B of A Securities Upgrades Neutral → Buy
05/24/2019 -34.31% RBC Capital $16 → $4.5 Downgrades Outperform → Sector Perform
04/02/2019 16.79% Barclays $6 → $8 Maintains Equal-Weight
04/02/2019 162.77% JMP Securities $16 → $18 Maintains Market Outperform
11/16/2018 118.98% Piper Sandler → $15 Reinstates → Overweight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/18/2023 45.99% 加拿大皇家銀行資本 $9→$10 升級 行業表現優於→
08/04/2023 31.39% 加拿大皇家銀行資本 $8→$9 維護 行業表現
08/04/2023 60.58% 傑富瑞 →$11 升級 持有→購買
08/04/2023 337.96% HC Wainwright公司 →$30 重申 購買→購買
08/03/2023 75.18% 李約瑟 $14→$12 重申 →購買
07/13/2023 45.99% B of A證券 →$10 升級 中性→購買
05/04/2023 31.39% 加拿大皇家銀行資本 →$9 重申 →行業表現
05/04/2023 104.38% 李約瑟 →$14 重申 →購買
04/20/2023 45.99% Evercore ISI集團 $13→$10 維護 跑贏大盤
04/20/2023 104.38% 李約瑟 →$14 重申 →購買
03/14/2023 45.99% 加拿大皇家銀行資本 →$10 重申 →行業表現
02/22/2023 133.58% JMP證券 →$16 重申 →市場跑贏大盤
02/22/2023 104.38% 李約瑟 →$14 升級 持有→購買
02/22/2023 337.96% HC Wainwright公司 →$30 重申 →購買
11/02/2022 133.58% Evercore ISI集團 →$16 升級 線內→表現優異
11/02/2022 89.78% 加拿大皇家銀行資本 $14→$13 維護 行業表現
2022/08/08 - 奧本海默 評級下調 超越→表現
08/05/2022 104.38% 巴克萊 $12→$14 維護 等重
08/05/2022 - 奧本海默 評級下調 超越→表現
08/05/2022 104.38% Evercore ISI集團 →$14 評級下調 勝過→同線
04/18/2022 89.78% 巴克萊 $22→$13 評級下調 超重→等重
04/12/2022 104.38% 加拿大皇家銀行資本 $16→$14 維護 行業表現
04/11/2022 104.38% B of A證券 →$14 評級下調 購買→中性
04/11/2022 133.58% 奧本海默 $20→$16 維護 跑贏大盤
2021年12月10日 133.58% 奧本海默 →$16 開始承保 →跑贏大盤
11/04/2021 104.38% 加拿大皇家銀行資本 $16→$14 維護 行業表現
11/04/2021 148.18% 巴克萊 $21→$17 維護 超重
08/06/2021 235.77% JMP證券 $22→$23 維護 市場表現強於大盤
08/06/2021 - 傑富瑞 評級下調 購買→Hold
08/06/2021 133.58% 加拿大皇家銀行資本 $13→$16 維護 行業表現
08/06/2021 206.57% 巴克萊 $20→$21 維護 超重
08/06/2021 337.96% HC Wainwright公司 $18→$30 維護
08/03/2021 206.57% 康託·菲茨傑拉德 →$21 開始承保 →超重
03/24/2021 177.37% HC Wainwright公司 $14→$19 維護
2021/01/22 31.39% 加拿大皇家銀行資本 $7→$9 維護 行業表現
12/07/2020 104.38% HC Wainwright公司 $13→$14 維護
11/24/2020 75.18% Evercore ISI集團 →$12 開始承保 →跑贏大盤
06/17/2020 - BTIG 開始承保 →中性
05/05/2020 2.19% 巴克萊 $4→$7 升級 等重→超重
2019年11月15日 - B of A證券 升級 中性→購買
2019年05月24日 -34.31% 加拿大皇家銀行資本 $16→$4.5 評級下調 跑贏→板塊表現
2019年02月04日 16.79% 巴克萊 $6→$8 維護 等重
2019年02月04日 162.77% JMP證券 $16→$18 維護 市場表現強於大盤
2018年11月16日 118.98% 派珀·桑德勒 →$15 恢復 →超重

What is the target price for BioCryst Pharma (BCRX)?

BioCryst Pharma(BCRX)的目標價格是多少?

The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by RBC Capital on September 18, 2023. The analyst firm set a price target for $10.00 expecting BCRX to rise to within 12 months (a possible 45.99% upside). 16 analyst firms have reported ratings in the last year.

加拿大皇家銀行資本於2023年9月18日報道了BioCryst Pharma(納斯達克:BCRX)的最新目標價。這家分析公司將目標價定為10.00美元,預計BCRX將在12個月內上漲至45.99%(可能上漲45.99%)。過去一年,有16家分析公司公佈了評級。

What is the most recent analyst rating for BioCryst Pharma (BCRX)?

BioCryst Pharma(BCRX)的最新分析師評級是什麼?

The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by RBC Capital, and BioCryst Pharma upgraded their outperform rating.

生物冷凍製藥(納斯達克代碼:BCRX)的最新分析師評級由加拿大皇家銀行資本提供,BioCryst Pharma上調了其表現優於大盤的評級。

When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?

BioCryst Pharma(BCRX)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與BioCryst Pharma的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。BioCryst Pharma的上一次評級是在2023年9月18日提交的,所以你應該預計下一次評級將在2024年9月18日左右提供。

Is the Analyst Rating BioCryst Pharma (BCRX) correct?

分析師對BioCryst Pharma(BCRX)的評級正確嗎?

While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a upgraded with a price target of $9.00 to $10.00. The current price BioCryst Pharma (BCRX) is trading at is $6.85, which is out of the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的BioCryst Pharma(BCRX)評級被上調,目標價為9.00美元至10.00美元。BioCryst Pharma(BCRX)目前的交易價格為6.85美元,超出了分析師的預測區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論